Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database
A subgroup of patients with MG require ICU admission and rescue therapy with IVIg or PE, indicative of poor disease control. New therapies are needed to improve disease control and reduce disease burden.
Authors
- Jean‐Philippe Camdessanché (ORCID: https://orcid.org/0000-0002-5282-6707)
- Guilhem Solé (ORCID: https://orcid.org/0000-0001-9599-6573)
- C. Blein (ORCID: https://orcid.org/0000-0003-0900-8351)
- Andoni Echaniz‐Laguna (ORCID: https://orcid.org/0000-0003-1012-9783)
- Mariana Ciumas
- Benjamin Grenier
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Pellegrin (FR)
- Hôpital Nord (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
Publication Details
- Journal
- European Journal of Neurology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1111/ene.16518
- Citations
- 4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- Argenx